COTROPBSCF: Comparison of the Results of Premature Babies Started Complementary Feeding

Sponsor
Hacettepe University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04499430
Collaborator
(none)
120
1
24.7
4.9

Study Details

Study Description

Brief Summary

Neurological-developmental evaluations and developmental outcomes-diagnoses of premature babies are evaluated according to corrected postnatal age. Based on the limited evidence available, it can be concluded that complementary feeding may be an appropriate age for most premature babies who have reached at least the third month, generally corrected. However, for premature babies born at different gestational weeks, these periods have a relatively different meaning. A more accurate timeframe can be found in terms of complementary nutrition by evaluating chronological age and motor development together. More prospective observational studies are needed in this regard in premature babies. In the literature, there are not enough studies on the transition time to the most appropriate complementary diet for premature babies. The investigators planned to do this prospective observational study. In this study, patient groups will be randomly selected after appropriate matching. Premature babies participating in the study will be handled in three main groups (six subgroups in total). The data will be added to the case report forms. In addition to routine follow-ups, families will be called on the phone monthly, information about their babies' nutrition will be asked, whether there is a problem, questions of families will be answered, and information about complementary nutrition will be provided. At the end of the study, all data will be collected and entered into the SPSS database, which will be created.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The transition to complementary feeding in premature babies (37 weeks and over) is recommended by both the World Health Organization (WHO) and the European Gastroenterology, Hepatology and Nutrition Association (ESPHGAN) for 4-6 months. However, a full consensus on the transition time to complementary feeding has not been achieved for premature babies. It is controversial whether premature babies (born 37th week of gestation) are corrected for complementary feeding in the sixth month or chronological sixth month. According to the known, there are no clinical studies investigating this topic in the literature.

    Neurological-developmental evaluations and developmental outcomes-diagnoses of premature babies are evaluated according to corrected postnatal age. Based on the limited evidence available, it can be concluded that complementary feeding may be an appropriate age for most premature babies who have reached at least the third month, generally corrected. However, for premature babies born at different gestational weeks, these periods have a relatively different meaning. A more accurate timeframe can be found in terms of complementary nutrition by evaluating chronological age and motor development together. More prospective observational studies are needed in this regard in premature babies. In the literature, there are not enough studies on the transition time to the most appropriate complementary diet for premature babies. The investigators planned to do this prospective observational study.

    In this study, patient groups will be randomly selected after appropriate matching. Premature babies participating in the study will be handled in three main groups (six subgroups in total).

    Before the transition to complementary nutrition of the groups included in the study, breast milk and / or formula food, nutritional supplement (such as breast milk enhancer, protein supplement) intake will be recorded. The same polyvitamin preparation will be used for all premature babies. In accordance with the recommendation of the World Health Organization, 2 mg / kg / day standard oral iron prophylaxis will be started to all premature babies starting from the second chronological month. Immunization will be done in accordance with the national vaccination program.

    The data will be added to the case report forms. In addition to routine follow-ups, families will be called on the phone monthly, information about their babies' nutrition will be asked, whether there is a problem, questions of families will be answered, and information about complementary nutrition will be provided. At the end of the study, all data will be collected and entered into the SPSS database, which will be created.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Comparison of the Results of Premature Babies Started Complementary Feeding in Adjusted or Chronologically in Their Sixth Month
    Actual Study Start Date :
    Jun 8, 2020
    Anticipated Primary Completion Date :
    Jun 30, 2022
    Anticipated Study Completion Date :
    Jun 30, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    1

    Group 1: 29 weeks and six days of gestation and earlier Group 1a: complementary feeding began chronologically in the sixth month Group 1b: Complementary feeding corrected at sixth month

    2

    Group 2: Those whose gestational age is between 30 weeks and 33 weeks and sixth days Group 2a: complementary feeding began chronologically in the sixth month Group 2b: complementary feeding started in the sixth month, corrected

    3

    Group 3: Those whose gestational age is between 34 weeks and 37 weeks and sixth day Group 3a: complementary feeding began chronologically in the sixth month Group 3b: complementary feeding started in the sixth month, corrected

    Outcome Measures

    Primary Outcome Measures

    1. the transition time to the most appropriate complementary diet for premature babies [24 months]

      . In the literature, there are not enough studies on the transition time to the most appropriate complementary diet for premature babies. We planned to do this prospective observational study.

    Secondary Outcome Measures

    1. Reaching the targeted number of patients [24 months]

      In this time we aim to reach the targeted number of patients

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    6 Months to 24 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male / female babies who were born before the mother at the Hacettepe University Children's Hospital Neonatal Intensive Care Unit and / or Hacettepe University Adult Hospital Maternity and Birth Service and were born earlier than 37 weeks.

    • Babies who are at the Hacettepe University Children's Hospital Neonatal Intensive Care Unit and / or Hacettepe University Adult Hospital Maternity and Maternity Service, were born earlier than 37 weeks and continue to be followed regularly in the neonatal outpatient clinic.

    • Babies whose informed consent was obtained for their participation by the family.

    Exclusion Criteria:
    • Babies with SGA (birth weight below 10th percentile according to gestational week) by birth weight

    • Babies with chromosomal anomalies

    • Babies diagnosed with hypoxic ischemic encephalopathy

    • Babies who have had major surgical operations (gastrointestinal anomaly, severe necrotizing enterocolitis requiring surgery, major gastrointestinal system anomaly, major congenital heart anomaly, diaphragmatic hernia)

    • Babies with exitus in the neonatal period

    • Babies who do not continue regular polyclinic follow-up after discharge

    • Babies of families who do not comply with the study protocol

    • Babies with missing study data

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hacettepe University Ankara Turkey

    Sponsors and Collaborators

    • Hacettepe University

    Investigators

    None specified.

    Study Documents (Full-Text)

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    H. Tolga Çelik, associate professor, Hacettepe University
    ClinicalTrials.gov Identifier:
    NCT04499430
    Other Study ID Numbers:
    • KA-20053
    First Posted:
    Aug 5, 2020
    Last Update Posted:
    Aug 7, 2020
    Last Verified:
    Aug 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by H. Tolga Çelik, associate professor, Hacettepe University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 7, 2020